Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
“Improved methodology for data collection on accidents and disabilities – Integration of European Injury Statistics” (INTEGRIS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Austria,Netherlands,Denmark,United Kingdom,Italy,Slovenia,France,Netherlands,Estonia,Ireland,Norway,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-05-01
End date: 2011-04-30
Duration (months): 36.0
Total project cost (EUR): 2805479.15
EU funding (EUR): 1975544.5
Participants: 13
Project status: CLOSED

The implementation of a prevention-oriented injury surveillance in the EU is a major demand towards the Member States in the recent “EC Council Recommendations on the prevention of injury and the promotion of safety”. Needed in particular are valid and reliable indicators for the array of external causes of injury morbidity, like involved activities, products and mechanisms, and for the most severe consequences of injuries besides death – long term and chronic disabilities . Whereas no single EU health statistics fulfills that demand to date, the integration of two existing data sources – the prevention-oriented European Injury Database (IDB ) and the routine Hospital Discharge Registers (HDR) – is considered the most promising approach to that avail. However, substantial methodological improvement in IDB sampling, research into the operationalization of disability indicators for the HDR, and technological advancement for a streamlined data collection for both data systems are required. The INTEGRIS project aims to provide the necessary research and technology input for the IDB-HDR integration through an evaluated demonstration project in six Member States. This aim links to chapter 4.2 of the call 2007 “Responding to EU policy needs in Health Statistics” in the field of hospital based injury statistics, 4.2.4: Health Statistics and Rare Events (HEALTH-2007) in particular. The resulting IDB-HDR data model and INTEGRIS prototype shall meet the statistical quality criteria of Eurostat (European Statistical System) and the public health requirements of the EU Health Indicators (ECHI ). A successful evaluation provided, an EU-level implementation plan will be proposed for adoption by the relevant stakeholders and decision makers.

Keywords: injuries,accidents,disabilities,health statistics,rare events
The Pathophysiology and Natural Course of Patients with Primary Antibody Deficiencies (PAD) (EURO-PADNET)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Sweden,Germany,Italy,Germany,Italy,France,United Kingdom,Czechia,Netherlands,Germany,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-05-01
End date: 2011-04-30
Duration (months): 36.0
Total project cost (EUR): 3942625.0
EU funding (EUR): 2986998.0
Participants: 13
Project status: CLOSED

This medium-sized collaborative project will document and monitor the natural course and study the pathophysiology of Primary Antibody Deficiencies (PAD). PADs are rare inborn errors of the immune system with an estimated incidence of <1:25.000. The defective immunity in patients with PAD causes an increased susceptibility to recurrent infections of the respiratory- and gastro-intestinal tract as well as ill defined co-morbidity including granulomatous disease, lymphocytic organ infiltration and (paradoxically) autoimmunity. Our consortium cares for more than 1000 PAD patients, representing approx. 50% of the patients registered in Europe, many of them being children. We propose to: 1. Combine clinical and research data in a central online registry, complemented by a sample repository (WP1) 2. Elucidate the genetic cause of PADs by linkage analysis and candidate gene approaches (WP2) 3. Establish in vitro models for B cell differentiation steps that are defective in PADs such as in vitro class switch recombination, and siRNA knockdown models for PAD screening (WP3) 4. Create mouse models of PAD by using several technology platforms including knock-in and knock-out mice, shRNA mediated gene knock-down and humanised mice (WP4) 5. Perform translational research by taking the observations from the patients into the basic research projects and transfer these results back to the patients (WP5) The study of these immunodeficiencies represent an ‘experiment of nature’, uniquely enabling researchers to study the detrimental effects of mutations in specific genes involved in the immune system. Basic research results are translated into the development of new technologies, new knowledge, and new therapeutic tools. The clinical results will improve the diagnosis, management and quality of life of PAD patients, leading to future developments of new tests, preventive measures and treatment protocols.

Keywords: immunodeficiency,antibody deficiency,genetic,database,clinical,immunoglobulin,mutation,candidate gene,class switch recombination,humanised mice,lentiviral vector
Rapid, robust & scaleable platform technology for fully automated reference laboratory grade Polymerase Chain Reaction (PCR) based diagnostics regardless of global setting (RANGER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Denmark,United Kingdom,United Kingdom,United Kingdom,Thailand,Netherlands,United Kingdom
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-07-01
End date: 2011-06-30
Duration (months): 36.0
Total project cost (EUR): 4170658.6
EU funding (EUR): 2982200.0
Participants: 9
Project status: CLOSED

RANGER addresses the HEALTH-2007-2.3.3-4: Innovative point-of-care (POC) diagnostic tests for influenza call by providing a innovative solution to the immediate need for a rapid, robust, cost effective & user friendly POC diagnostic for influenza. We will develop the following real-time PCR system: 1) A robust, portable system allowing testing at the POC anywhere in the world 2) Raw sample to result automation of the entire test process including sample preparation 3) Parallel processing of multiple samples & different sample types (aspirates & swabs) in a modular, user-friendly system 4) RAPID & simple positive/negative result to the end user 5) No need for an external computer or laboratory equipment 6) Low cost consumable & reagents with a target cost of < €10 per test 7) Sample preparation & freeze dried reagents pre-packaged into an ambient stable consumable to eliminate cold storage chains 8) High confidence PCR results providing sensitivity & specificity equivalent to reference laboratory assays a. Suitable for the diagnosis of early stage infections where viral titres can be low b. Applicable to late surveillance & can be used to confirm the results from lower cost, low performance screen tests such as antibody assays that have low sensitivity and specificity. c. Simultaneous identification of specific influenza strains & viral subtypes using multiplexing real-time PCR assays will also allow exclusion of related respiratory diseases 9) Surveillance Management software & geographical data using GPS, allowing health authorities to manage early stage epidemics. The RANGER consortium includes WHO reference sites for human influenza diagnostics & world leading companies to develop and validate a POC influenza diagnostic system within 2 years. This system will allow health systems to be better prepared for epidemics by enabling early identification of infection and thus timely implementation of containment/treatment strategies.

Keywords: polymerase chain reaction,pcr,poc,molecular diagnostics,influenza
MULTIMODAL SKIN INSPECTION WITH HYBRID ACOUSTIC & OPTICAL SPECTROSCOPIC IMAGING (SKINSPECTION)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Italy,Germany,Germany,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-04-01
End date: 2012-03-31
Duration (months): 48.0
Total project cost (EUR): 5232072.0
EU funding (EUR): 4097585.0
Participants: 6
Project status: CLOSED

The incidence of skin cancer in Europe, US, and Australia is rising rapidly. One in five will develop some form of skin cancer during the lifetime. A person has a 1:33 chance to develop melanoma, the most aggressive skin cancer. Melanoma is the second most common cancer in women aged 20-29, and the sixth most common cancer in men and women. In 2007, more than 1 million new cases will be diagnosed in the US alone. About 90% of skin cancers are caused by ultraviolet (UV) sun light. The World Health Organization estimates that 60,000 people will die this year from too much sun: 48,000 from melanoma and 12,000 from other skin cancer. A significant improvement of the current diagnostic tools of dermatologists is required in order to identify dermal disorders at a very early stage as well as to monitor directly the effects of treatment. We suggest within this proposal the development of a non-invasive multimodal hybrid imaging system with the capability to perform non-invasive high resolution three-dimensional clinical (i) two-photon imaging with time-correlated single photon detection, (ii) autofluorescence lifetime imaging, (iii) high-frequency acoustical imaging with novel miniaturized multiple detector arrays, and (iv) optoacoustical imaging using ultrashort near infrared (NIR) laser pulses. This novel multimodal approach will provide a wide-field “acoustic/optoacoustic” view with quantitative depth information of the dermatological lesion as well as a close “optical” look into particular intratissue compartments with quantitative hyperspectral information and subcellular resolution. A successful project will provide a novel unique tool for early diagnosis and treatment control of skin cancer and skin disease and will significantly contribute to the improvement of the European health care system.

Keywords: skin cancer,flim,ultrasound,optoacoustics,multiphoton imaging
Embryonic Stem cell-based Novel Alternative Testing Strategies (ESNATS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,European organisations area,United Kingdom,Switzerland,Germany,Estonia,Belgium,Sweden,Germany,Netherlands,United Kingdom,Belgium,Germany,France,United Kingdom,Denmark,Spain,Germany,Germany,Italy,Germany,United Kingdom,United Kingdom,Germany,Italy,Israel,Netherlands,Sweden
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-04-01
End date: 2013-09-30
Duration (months): 66.0
Total project cost (EUR): 15592219.98
EU funding (EUR): 11895577.0
Participants: 33
Project status: CLOSED

ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to inter-species variation - non-ESC assays rely on primary cells or cells of malignant origin that are hard-to-standardise and limited in regard to quantity, homogeneity and genetic diversity - existing assay systems based on primary animal cell lines do not reliably represent the physiological situation ESNATS will develop a battery of toxicity tests using hESC lines subjected to different standardised culture protocols. Tests will cover embryoid bodies in different developmental stages and differentiated derivatives including gamete and neuronal lineages, complemented with test systems for hepatic metabolism. Predictive toxicogenomics and proteomics markers will be identified. The individual tests will be integrated into an "all-in-one" test system. To enable future industrial use ESNATS will prepare automating and scaling up of hESC culture. The predictivity, quality and reproducibility of ESNATS will be evaluated in a proof of concept study. ESNATS benefits are to increase safety due to better predictivity of human test systems, to reduce, refine and replace animal tests, to lower testing cost, and to support medium/high throughput testing. ESNATS objectives will be achieved in a 5 year multi-disciplinary collaboration of leading European researchers in alternative testing, toxicology, ESC research, genomics, modelling, and automation. The consortium will also include representatives from regulatory bodies, the pharmaceutical industry and ethical advisors to provide guidance to ensure rapid applicability of the developed tests systems.

Keywords: alternative testing,embryonic stem cells,reproductive toxicity,cns toxicity,toxicogenomics,hepatic metabolism,cocktail effects
Planets - The Solar System and Beyond (PLANETARYSYSTEMS)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Systems and communication engineering
Countries involved: Israel
Call:  (ERC-2007-StG, 2007)
Start date: 2008-06-01
End date: 2013-05-31
Duration (months): 60.0
Total project cost (EUR): 1000000.0
EU funding (EUR): 1000000.0
Participants: 1
Project status: CLOSED

The discovery of the first extra solar planet, merely twelve years ago, ushered an explosive growth in our knowledge of planetary systems. Extrasolar planets have been detected with ever-smaller masses and today Earth analogs orbiting other stars are on the discovery horizon! Observations of disks around young stars reveal the initial conditions for planet formation while detections of debris disks probe post formation stages. Closer to home, exploration of the Kuiper Belt provides new clues on planet migration and on the intermediate stages of planetary accretion. Some discoveries, like extrasolar planets with short orbital periods and high eccentricities, have led to a complete overhaul of previously accepted planet formation theories. The increasing wealth of observations creates a unique opportunity to answer fundamental questions pertaining to planets and planetary systems. The relevant objects include on one hand giant extrasolar planets, a thousand times more massive than Earth, and on the other hand rocky and icy Kuiper Belt Objects, a millionth of the Earth mass. The physical processes vary from the resonant interaction of giant extrasolar planets with gas disks to collisions of solid bodies in the outer solar system. Still, much of the underlying physics, especially orbital dynamics, is common. We propose, therefore, an innovative program of integrated studies of the above subjects. A unique aspect of my group’s approach is utilizing the common physics for a synergic treatment of these traditionally separated topics. By answering open questions in dynamics, investigating the inner workings of planetesimal coagulation and interpreting the properties of extrasolar planets we will make significant breakthroughs in the understanding of planet formation and its possible outcomes. This will illuminate our place in the universe and will guide farther searches of planets. Our exploration is at the beginning of a long voyage seeking life around nearby stars.

Keywords: extrasolar planets
Small Molecule Inhibitors of the Trimeric Influenza Virus Polymerase Complex (FLUINHIBIT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Lithuania,Germany,Italy,Switzerland,Austria
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-04-01
End date: 2010-03-31
Duration (months): 24.0
Total project cost (EUR): 1936867.0
EU funding (EUR): 1484250.0
Participants: 6
Project status: CLOSED

The clock is counting down to the next influenza pandemic. Since 1997, the avian influenza virus strain H5N1 has infected over 250 people worldwide with a fatality rate of ~60%, although so far without sustained human-to-human transmission. In view of the very few efficacious drugs against influenza virus infections and the time it takes to develop a matching vaccine, there is an unmet worldwide need for new anti-influenza drugs. The viral trimeric RNA polymerase complex, consisting of the subunits PA, PB1 and PB2, is an attractive target for inhibition of viral replication. However, due to the absence of detailed structural information and clear understanding of the subunit functions so far, inhibitors of the RNA polymerase developed as drug candidates are extremely scarce. Based on the recent finding that a short peptide corresponding to the PA-binding domain of the PB1 subunit blocks both polymerase activity and viral spread, FLUINHIBIT aims at discovering small molecule inhibitors of this subunit interaction crucial for viral replication. Starting from the peptide, and supported by characterization of the PB1-binding domain of PA, molecular modeling will be employed to rationally design and synthesize peptidomimetics via traditional medicinal chemistry and a novel fragment based library synthesis approach. In parallel, a fluorescence polarization high-throughput assay will be developed to screen large compound collections and unique in-house small molecule libraries. The resulting hits will be profiled in cell-based assays and lead candidates with antiviral activity will be identified for preclinical development.

Keywords: influenza,polymerase,inhibitor,drug design,high-throughput screening
Development of a two-approach plate system for the fast and simultaneous detection of MDR and XDR M. tuberculosis (FAST-XDR-DETECT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Belgium,Germany,Sweden,Argentina,Latvia,Colombia
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-02-01
End date: 2012-01-31
Duration (months): 48.0
Total project cost (EUR): 3639320.0
EU funding (EUR): 2695565.0
Participants: 8
Project status: CLOSED

Tuberculosis (TB) continues being a leading cause of death due to a single infectious disease agent. The HIV/AIDS pandemic and the emergence of drug resistance are compounding factors that hinder the control of the disease. Associated with this problem is the emergence of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, defined as strains resistant to at least isoniazid and rifampicin, the most valuable drugs in the treatment of the disease. More recently, the appearance of extensively drug resistant (XDR) strains has been reported. These strains, in addition to being MDR, are also resistant to key second-line drugs. Patients, especially HIV patients, harbouring XDR strains have virtually no treatment options. New and improved methods for fast detection of drug resistance are urgently needed. This project will develop a twofold-approach system for the fast and simultaneous detection of MDR and XDR strains based on a rapid phenotypic assay and a genotypic test. Colorimetric methods, which have been previously validated by our group for first-line drug susceptibility testing, will be developed for key second-line drugs involved in XDRTB. Once set up, these methods will be further elaborated for direct application to sputum specimens. The molecular tool will be based on a modification of the novel technology named detection of immobilized amplified product in one phase system. This single step amplification method will be developed in a versatile microtitre well strip format for detection first of MDR and then of XDR strains. The tools will be then validated in different settings and prospectively evaluated in target populations. The project will contribute to the currently available armamentarium for rapid detection of drug resistant TB and will introduce new tools for the detection of the recently-described and highly-lethal XDRTB. It will also contribute to our knowledge on the mechanisms of M. tuberculosis resistance to second-line drugs.

Keywords: tuberculosis,drug resistance,mdr,xdr,fast detection,new tests
Light and complexity (COMPLEXLIGHT)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Fundamental constituents of matter
Countries involved: Italy
Call:  (ERC-2007-StG, 2007)
Start date: 2008-05-01
End date: 2013-04-30
Duration (months): 60.0
Total project cost (EUR): 1085000.0
EU funding (EUR): 1085000.0
Participants: 1
Project status: CLOSED

The project is aimed at funding a multi-disciplinary laboratory on nonlinear optics and photonics in soft-colloidal materials and on “complex lightwave systems”. A team of talented young researchers, divided among experiments, theory, parallel computation and nano-fabrication is involved. The proposed research will foster several breakthrough discoveries from soft-matter to biophysics, from nonlinear and integrated optics to the science of complexity and cryptography. The underlying vision is driven by the physics of complex systems, those displaying a large number of thermodynamically equivalent states and emergent properties. There are 4 original and high-impact activities, which explore applicative potentialities: 1) sub-wavelength light filaments in soft- and bio-matter; 2) lasers in soft-matter and bio-tissues; 3) control of soft-matter lasers by light filaments; 4) complex lightwave systems, encryption by nano-structured disordered lasers. Activity 1 will lead to ultra-thin re-addressable light beams (sub-wavelength spatial solitons) propagating in soft- and bio-matter that can be used in laser-surgery, matter manipulation and able to guide high power laser pulses; activity 2 attains novel structural diagnostic techniques in bone tissue surpassing limits of nuclear magnetic resonance imaging, and assesses the field of lasers in soft-materials; activity 3 will demonstrate the control of self-organization processes in soft-matter by light filaments probed by laser emission; activity 4 is based on specific features mutuated from spin-glass theory, and will realize a novel cryptographic technique superior to chaotic systems in terms of security. Activity 1 and 2 are propaedeutic to the others. The team is composed by the Principal Investigator (P.I.), 4 post-doctoral researchers and 3 Ph.D. students. The budget will be used for paying the P.I., two post-doctoral positions, laser sources, high performance computing facilities, and instrumentation.

Keywords: bio-physics,complex information,soft-matter,solitons,random laser,vcsel,spin-glass theory,nuclear magnetic resonance,lightwave systems,parallel and distributed computing